Mackenzie Financial Corp Esperion Therapeutics, Inc. Transaction History
Mackenzie Financial Corp
- $65.9 Billion
- Q1 2025
A detailed history of Mackenzie Financial Corp transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 123,115 shares of ESPR stock, worth $142,813. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,115
Previous 143,252
14.06%
Holding current value
$142,813
Previous $315,000
43.81%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$16.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$13.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$12.7 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$11.2 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$8.04 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $77.2M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...